IL33 and neoplasm: Previous research has identified regulatory T cells and myeloid-derived suppressor cells as primary targets of IL-33 [5,60], reinforcing the potential benefit of tropisetron-mediated IL-33 suppression in reversing the immunosuppressive tumor microenvironment in PDAC.